Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries

Pediatric Drugs

Volumn 14, Issue 6, 2012, Pages 429-433

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Spotlights; Gastroenteritis; Pharmacoeconomics; RIX 4414; Rotavirus vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ANOREXIA; CHILD HOSPITALIZATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DEVELOPING COUNTRY; DIARRHEA; DRUG COST; FEVER; HUMAN; IRRITABILITY; LOWEST INCOME GROUP; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RHINORRHEA; ROTAVIRUS INFECTION; SENSITIVITY ANALYSIS; SIDE EFFECT; VACCINATION; VIRAL GASTROENTERITIS; VOMITING;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; GASTROENTERITIS; HUMANS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 84867359228     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/bf03262423     Document Type: Review

References (66)

1. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg InfectDis 2003May; 9 (5): 565-72 (Pubitemid 36529515)
2. Leung AK, Kellner JD, Davies HD. Rotavirus gastroenteritis. Adv Ther 2005; 22 (5): 476-87 (Pubitemid 43130865)
3. Cortese MM, Parashar UD, Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009 Feb 6; 58 (RR-2): 1-25
4. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006 Aug 11; 55 (RR-12): 1-13
5. Gray J, Vesikari T, Van Damme P, et al. Rotavirus. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl. 2: S24-31 (Pubitemid 351644167)
6. Clark HF, Offit PA. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann 2004 Aug; 33 (8): 536-43 (Pubitemid 39079062)
7. Soriano-Gabarro M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in EuropeanUnion countries. Pediatr Infect Dis J 2006; 25 Suppl. 1: S7-11
8. Grimwood K, Lambert SB, Milne RJ. Rotavirus infections and vaccines: burden of illness and potential impact of vaccination. Pediatr Drugs 2010; 12 (4): 235-56
9. Parashar UD, Gibson CJ, Bresse JS, et al. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006 Feb; 12 (2): 304-6
10. Velazquez FR. Protective effects of natural rotavirus infection. Pediatr Infect Dis J 2009 Mar; 28 (3 Suppl.): S54-6
11. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15 (1): 29-56 (Pubitemid 40070041)
12. Diez-Domingo J, Baldo J-M, PatrzalekM, et al. Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis among children aged less than 5 years in six European countries. Eur J Pediatr 2011 Feb; 170 (2): 213-22
13. Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007 May 1; 195 Suppl. 1: S4-16
14. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl JMed 1996 Oct 3; 335 (14): 1022-8 (Pubitemid 26338732)
15. Bhan MK, Lew JF, Sazawal S, et al. Protection conferred by neonatal rotavirusinfection against subsequent rotavirus diarrhea. J Infect Dis 1993 Aug; 168 (2): 282-7 (Pubitemid 23210600)
16. Bishop RF, Barnes GL, Cipriani E, et al. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983 Jul 14; 309 (2): 72-6 (Pubitemid 13063589)
17. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl. 2: S38-48 (Pubitemid 351644169)
18. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics 2009 May; 123 (5): 1412-20
19. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008 May; 46 (5): 615-8
20. Global Advisory Committee on Vaccine Safety. Report of meeting held 17-18 June 2009. Wkly Epidemiol Rec 2009 Aug 7; 84 (32): 325-32
21. World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009: conclusions and recommendations. Wkly Epidemiol Rec 2009 Jun 5; 84: 220-35
22. World Health Organization. Global use of rotavirus vaccines recommended [media release; online]. Available from URL: http://www.who.int/mediacentre/ news/releases/2009/rotavirus-vaccines-20090605/en/index.html# [Accessed 2011 May 24]
23. McCormack PL, Keam SJ. Rotavirus vaccine RIX4414 (Rotarix™): a review of its use in the prevention of rotavirus gastroenteritis. Paediatr Drugs 2009; 11 (1): 75-88
24. Plosker GL. Pentavalent rotavirus vaccine (RotaTeq®): a review of its use in the prevention of rotavirus gastroenteritis in Europe. Drugs 2010 Jun 18; 70 (9): 1165-88
25. Babar ZU, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28 (12): 1069-74
26. Shafie AA, Hassali MA. Is there a role for pharmacoeconomics in developing countries? [letter; author reply 84-86]. Pharmacoeconomics 2011; 29 (1): 83-84s
27. World Bank. World Bank list of economics (January 2011) [online]. Available from URL: http://siteresources.worldbank.org/DATASTATISTICS/Resources/ CLASS.XLS [Accessed 2011 May 24]
28. Linhares AC, Velazquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008 Apr 5; 371 (9619): 1181-9 (Pubitemid 351458523)
29. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl JMed 2010 Jan 28; 362 (4): 289-98
30. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006 Jan; 354 (1): 11-22 (Pubitemid 43048947)
31. TregnaghiMW, Abate HJ, Valencia A, et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 2011; 30 (6): e103-8
32. Gurgel RG, Bohland AK, Vieira SC, et al. Incidence of rotavirus and all-causediarrhea in northeast Brazil following the introduction of a national vaccination program. Gastroenterology 2009 Dec; 137 (6): 1970-5
33. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010 Jan 28; 362 (4): 299-305
34. Quintanar-Solares M, Yen C, Richardson V, et al. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children < 5 years of age in Mexico. Pediatr Infect Dis J 2011 Jan; 30 (1 Suppl.): S11-5
35. Yen C, Armero Guardado JA, Alberto P, et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 2011 Jan; 30 (1 Suppl.): S6-10
36. de Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccinationagainst childhood diarrhoea in El Salvador: case-control study. BMJ 2010 Jun 15; 340: c2825
37. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 2010 Feb 1; 201 (3): 363-9
38. GlaxoSmithKline. Rotarix (rotavirus vaccine, live, oral) US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2011 Feb
39. GlaxoSmithKline Biologicals s.a. Rotarix® EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000639/WC500054789.pdf [Accessed 2011 Mar 14]
40. Atherly D, Dreibelbis R, Parashar UD, et al. Rotavirus vaccination: costeffectiveness and impact on child mortality in developing countries. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S28-38
41. Berry SA, Johns B, Shih C, et al. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010 Sep; 202 Suppl.: S108-15
42. Clark AD, Walker DG, Mosqueira NR, et al. Cost-effectiveness of rotavirus vaccination in Peru. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S114-24
43. Constenla DO, Linhares AC, Rheingans RD, et al. Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr 2008 Dec; 26 (4): 388-96
44. Constenla D, Velazquez FR, Rheingans RD, et al. Economic impact of a rotavirus vaccination program in Mexico. Rev Panam Salud Publica 2009 Jun; 25 (6): 481-90
45. Esposito DH, Tate JE,KangG, et al. Projected impact and cost-effectiveness of a rotavirus vaccination programin India, 2008. Clin Infect Dis 2011; 52 (2): 171-7
46. Podewils LJ,Antil L,Hummelman E, et al. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005 Sep 1; 192 Suppl. 1: S133-45 (Pubitemid 41193115)
47. Tate JE, Kisakye A, Mugyenyi P, et al. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine 2011 Jan 14; 29: 3329-34
48. Ortega O, El-Sayed N, Sanders JW, et al. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S92-8
49. Chotivitayatarakorn P, Chotivitayatarakorn P, Poovorawan Y. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children. Southeast Asian J TropMed Public Health 2010 Jan; 41 (1): 114-25
50. De la Hoz F, Alvis N, Narvaez J, et al. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. Vaccine 2010 May 14; 28 (22): 3856-64
51. Isakbaeva ET, Musabaev E, Antil L, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007 Jan 4; 25 (2): 373-80 (Pubitemid 44856079)
52. Tate JE, Rheingans RD, O'Reilly CE, et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S76-84
53. Wang XY, Riewpaiboon A, von Seidlein L, et al. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin Infect Dis 2009 Oct 15; 49 (8): 1202-10
54. de Soárez PC, Valentim J, Sartori AM, et al. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008 Apr; 23 (4): 221-30
55. Fischer TK, Anh DD, Antil L, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005 Nov 15; 192 (10): 1720-6 (Pubitemid 41587821)
56. Flem ET, Latipov R, Nurmatov ZS, et al. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in Kyrgyzstan. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S195-202
57. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health 2009; 9: 29
58. Rheingans RD, Antil L, Dreibelbis R, et al. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009 Nov 1; 200 Suppl. 1: S16-27
59. Rose J, Hawthorn RL, Watts B, et al. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 2009; 339: b3653
60. Wilopo SA, Kilgore P, Kosen S, et al. Economic evaluation of a routine rotavirus vaccination programme in Indonesia. Vaccine 2009 Nov 20; 27 Suppl. 5: F67-74
61. Kim SY, Sweet S, Slichter D, et al. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010; 10: 253
62. World Health Organization. Some strategies to reduce risk. In: WHO. The world health report 2002: reducing risks, promoting healthy life. Geneva: WHO, 2002 [online]. Available from URL: http://www.who.int/whr/2002/en/[Accessed 2011 Jun 28]
63. World Bank. World development report 1993: investing in health. Washington, DC: Oxford University Press, 1993
64. Murray CJL, Lopez AD. The global burden of disease. Vol. I of global burden of disease and injury series. Cambridge (MA): Harvard University Press, 1996
65. Shillcutt SD, Walker DG, Goodman CA, et al. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009; 27 (11): 903-17
66. Plosker GL. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. Pharmacoeconomics 2011; 29 (11): 989-1009